apfcbAPFCB eNewscoAPFCB News Volume 4, Issue 2MultidisciplinaryEnglishJul-Dec, 2025NNY20250831ArticlesThe Non-Malignant Face of CA-125EnglishY132134Dr. VivekPantEnglishNDr. SantoshPradhanEnglishYDr. KeyoorGautamEnglishYDr. DevishPyakurelEnglishYDr. AbhaShresthaEnglishYDr. NehaNeupaneEnglishY10.62772/APFCB-News.2025.4205Carbohydrate antigen 125 (CA -125) is widely used as a tumor marker for ovarian cancer, but elevations can occur in benign conditions, leading to diagnostic dilemmas. We report a case of markedly elevated CA 125 in a 62-year-old woman due to pericardial effusion secondary to idiopathic pericarditis. Her CA -125 normalized following pericardiocentesis and treatment, highlighting the importance of interpreting tumor markers within clinical context.EnglishCA-125; Pericardial Effusion, Non-malignant cause;, Tumor Markerhttps://apfcb.org/APFCB_News/abstract?id=40References16191. Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H. New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Medical hypotheses. 2012 Sep 1;79(3):381-3.2. Scholler N, Urban N. CA125 in ovarian cancer. Biomarkers in medicine. 2007 Dec 1; 1(4):513-23.3. Lloyd KO, Yin BW. Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH: OVCAR-3. Tumor biology. 2000 Dec 15; 22(2):77-82.4. Lei Y, Zang R, Lu Z, Zhang G, Huang J, Liu C et al. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. Cell Death and;amp; Disease. 2020 Oct 14; 11(10):853.5. Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Advances in cancer biomarkers: from biochemistry to clinic for a critical revision. 2015 Jan 1:229-44.6. Miralles C, Orea M, Espana P, Provencio M, Sand;aacute;nchez A, Cantos B et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Annals of Surgical Oncology. 2003 Mar;10(2):150-4.7. Nand;uacute;and;ntilde;ez J, Minana G, Nand;uacute;and;ntilde;ez E, Chorro FJ, Bodand;iacute; V, Sanchis J. Clinical utility of antigen carbohydrate 125 in heart failure. Heart failure reviews. 2014 Sep;19(5):575-84.8. Lland;agrave;cer P, Bayand;eacute;s-Genand;iacute;s A, Nand;uacute;and;ntilde;ez J. Carbohydrate antigen 125 in heart failure. A New era in the monitoring and control of treatment. Medicina Cland;iacute;nica (English Edition). 2019 Apr 5;152(7):266-73.9. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. European journal of heart failure. 2006 May;8(3):270-4.10. Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. International journal of cardiology. 2010 Nov 5;145(1):71.11. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. European heart journal. 2005 Nov 1;26(22):2368-74.